-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The Company Reaps Abundant Results at the 2019 China Chemical Pharmaceutical Industry Annual Summit
Category:
发布时间：2019-10-29
【概要描述】
On October 10, the “2019 China Chemical Pharmaceutical Industry Annual Summit and the Launch Ceremony of the ‘Pharmaceutical Industry Blue Book’” was held in Nanchang, where the company once again received multiple prestigious awards. Shi Jianhui, Secretary of the Company’s Party Committee, attended the event by invitation.
On October 10, the “2019 China Chemical Pharmaceutical Industry Annual Summit and the Launch Ceremony of the Blue Book on the Pharmaceutical Industry” was held in Nanchang, where the company once again received multiple prestigious awards. Shi Jianhui, Secretary of the Company’s Party Committee, attended the event by invitation.
During the conference, the China Association for Pharmaceutical Industry held a launch ceremony for the “2019 Pharmaceutical Industry Blue Book.” Wen Zaixing, former Director-General of the Department of Commerce, delivered a speech at the ceremony. Qu Jiguang, Chairman of the company, served as the executive chief editor of the book. The “2019 Pharmaceutical Industry Blue Book” comprises 12 major sections: a general report; a section on pharmaceutical reform; a section on policies and regulations; a section on industry development; a section on special-topic reports; a section on scientific and technological innovation; a section on quality standards; a section on green pharmaceuticals; a section on credit-building; a section on regional development; a section on international exchanges; and an appendix. The book focuses on in-depth analysis and research into the development of the pharmaceutical industry and related topical issues, and is characterized by its authority, comprehensiveness, systematic approach, and practical utility, making it a widely referenced resource both within and outside the industry.
Meanwhile, during the conference, the “2019 List of Outstanding Enterprises and Product Brands in China’s Chemical Pharmaceutical Industry,” jointly organized and recommended by the China Association for Pharmaceutical Industry, the China Pharmaceutical Commerce Association, the China Over-the-Counter Drugs Association, the China Pharmaceutical Enterprise Development Promotion Association, and Sinopharm Reed Exhibitions Co., Ltd., was unveiled. At the event, the company was honored with a total of five awards: Top 100 Industrial Enterprises in Terms of Overall Strength in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Export-Oriented Formulation Enterprise Brand in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Enterprise Brand for Promoting the Integration of Informatization and Industrialization in China’s Chemical Pharmaceutical Industry for 2019; Outstanding Product Brand in the Categories of Water, Electrolyte and Acid–Base Balance Regulation, as well as Mineral and Nutritional Supplements in China’s Chemical Pharmaceutical Industry for 2019; and Outstanding Product Brand in the Blood and Hematopoietic System Category in China’s Chemical Pharmaceutical Industry for 2019.
Since its inception in 2011, the summit has been held consecutively for nine sessions, with this edition focusing on the theme of “Quality, Integrity, and Brand.” The event brought together representatives from relevant government departments, provincial and municipal pharmaceutical industry associations, pharmaceutical manufacturers, and upstream and downstream enterprises in the pharmaceutical value chain.
Over the years, the company has steadfastly adhered to the philosophy of “Technology Creates the Future,” achieving intelligent transformation of its production workshops. By leveraging technology to enhance product quality, the company has earned recognition from the market and various sectors of society for its superior quality, thereby driving corporate growth. The product portfolio has continued to expand, with the proportion of high-value-added offerings steadily increasing, bolstering market appeal and enabling exports to more than 80 countries and regions. Meanwhile, the company’s brand value has further increased, its brand influence has strengthened, and its reputation within the industry has improved steadily.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091